Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
28,54 EUR | -0,97% | +8,92% | -30,43% |
23/04 | Pharma Mar, S.A. rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024 | CI |
29/02 | Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024 |
Vakgebied
Aantal werknemers: 509
Verkoop per activiteit
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Oncology
99,2
%
| 191 | 97,4 % | 157 | 99,2 % | -17,96% |
Diagnostics
0,8
%
| 5 | 2,6 % | 1 | 0,8 % | -76,79% |
RNAi
0,1
%
| 0 | 0,0 % | 0 | 0,1 % | +290,32% |
Verkoop per regio
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Ireland
47,6
%
| 87 | 44,2 % | 75 | 47,6 % | -13,17% |
France
19,0
%
| 17 | 8,9 % | 30 | 19,0 % | +72,54% |
Other
8,6
%
| 13 | 6,7 % | 14 | 8,6 % | +4,17% |
United States
7,9
%
| 13 | 6,8 % | 13 | 7,9 % | -6,40% |
Rest of the European Union
6,9
%
| 19 | 9,6 % | 11 | 6,9 % | -42,40% |
Spain
4,4
%
| 17 | 8,5 % | 7 | 4,4 % | -58,36% |
Germany
2,9
%
| 15 | 7,6 % | 5 | 2,9 % | -69,05% |
Italy
2,6
%
| 15 | 7,7 % | 4 | 2,6 % | -72,40% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | - | 30-04-86 | |
Director of Finance/CFO | - | 01-01-88 | |
Chief Tech/Sci/R&D Officer | - | - | |
Chief Tech/Sci/R&D Officer | - | 01-01-03 | |
Compliance Officer | - | 01-04-20 | |
Ali Zeaiter
CTO | Chief Tech/Sci/R&D Officer | 47 | 01-01-18 |
Chief Tech/Sci/R&D Officer | - | 01-01-97 | |
Nadia Badri
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-11 |
Investor Relations Contact | - | 01-01-15 | |
Sales & Marketing | - | 01-03-12 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | - | 30-04-86 | |
Director/Board Member | - | 30-04-86 | |
Director/Board Member | - | - | |
Director/Board Member | 79 | - | |
Director/Board Member | 78 | - | |
Director/Board Member | - | 25-06-19 | |
Director/Board Member | - | 29-06-22 | |
Mera Ortega
BRD | Director/Board Member | - | - |
Director/Board Member | - | 29-06-22 | |
Director/Board Member | - | 21-12-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 18 354 907 | 13 713 346 ( 74,71 %) | 715 000 ( 3,895 %) | 74,71 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
PHARMA MAR, S.A. 3.52% | 652 235 | 3.52% | 20 244 853 $ |
Bedrijfsgegevens
Pharma Mar SA
Avenida de los Reyes, 1 Polígono Industrial La Mina
28770, Colmenar Viejo
+34 91 846 60 00
http://www.pharmamar.comSector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-30,43% | 545 mln. | |
-4,66% | 87,53 mld. | |
+2,63% | 40,42 mld. | |
-21,76% | 29,48 mld. | |
+55,96% | 25,43 mld. | |
-14,78% | 15,59 mld. | |
-18,49% | 11,49 mld. | |
-15,61% | 11,1 mld. | |
-44,02% | 11,3 mld. | |
+4,27% | 8,75 mld. |